Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06158139 · ClinicalTrials.gov registry record · Phase 1
Autologous CAR-T Cells Targeting B7-H3 in PDAC
A Phase 1 study of Pancreas Cancer and Relapse, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT06158139 is a Phase 1 study of Pancreas Cancer and Relapse that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 27 participants, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06158139, a Phase 1 study of Pancreas Cancer and Relapse, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration.
Conditions Studied
Interventions
- BIOLOGICAL iC9-CAR.B7-H3 T cell infusion
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2024-07-18 |
| Est. Completion | 2030-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06158139
The ClinicalTrials.gov registry entry for NCT06158139 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (97% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreas Cancer appearing as the primary indexed condition, and to 1 intervention - of which iC9-CAR.B7-H3 T cell infusion is the first listed.
NCT06158139 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06158139 about?
NCT06158139 is a clinical study titled "Autologous CAR-T Cells Targeting B7-H3 in PDAC". The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after rece...
What is the current status of trial NCT06158139?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2024-07-18. Estimated completion is 2030-04.
What conditions does trial NCT06158139 study?
This clinical trial studies the following conditions: Pancreas Cancer, Relapse, Resistant Cancer.
What interventions are being tested in trial NCT06158139?
The interventions under investigation include: iC9-CAR.B7-H3 T cell infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT06158139?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06158139 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 1
-
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.